BiomX To Present Pre-clinical Data at the Plenary Session of the AACR Microbiome, Viruses, and Cancer Conference

Download as PDF

NESS ZIONA, Israel--(BUSINESS WIRE)-- BiomX, a microbiome company developing both natural and engineered phage therapies, today announced that the company will present pre-clinical data from its colorectal cancer program at the plenary session of the American Association for Cancer Research (AACR) Microbiome, Viruses, and Cancer Conference taking place from February 21-24, 2020, in Orlando, Florida. BiomX’s colorectal cancer program utilizes phage to target bacteria that are naturally present within tumors, with the aim of converting ‘cold’ tumors to ‘hot’ by delivering a payload (i.e. an immunostimulatory payload) to the tumor and eradicating tumor-protective bacteria.

Details of the presentation are as follows:

Abstract Title: “Novel Phages Targeting The Intratumor Associated Bacteria Fusobacterium Nucleatum”
Date: Sunday, February 23, 2020
Time: 10:15 a.m. – 12:15 p.m. ET
Plenary Session 5: Oncogenic Viruses, Part 2
Poster Number: B20

About Phage Therapy
Bacteriophage, or phage, are viruses that target bacteria and are considered inert to mammalian cells. Phage are designed to target and kill specific bacterial species or strains without disrupting other bacteria or the healthy microbiota. All of BiomX’s phage-based product candidates derive from its proprietary platform, which is first used to discover and validate the association of specific bacterial strains with human diseases or conditions, and is then used to develop rationally-designed phage combinations (“cocktails”) of naturally occurring or synthetic phage to target pathogenic bacteria. The phage cocktails contain multiple phage with complementary functions optimized through in vitro and in vivo testing.

About BiomX
BiomX is a clinical-stage biotechnology company developing both natural and engineered phage cocktails designed to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC), and colorectal cancer (CRC). BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.
www.biomx.com

Safe Harbor Language
This press release contains certain “forward-looking statements” within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “target,” “believe,” “expect,” “will,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on BiomX management’s current beliefs, expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. You should review additional disclosures we make in our filings with the Securities and Exchange Commission (the “SEC”), which are available on the SEC’s website at www.sec.gov.

Company Contact
BiomX
Assaf Oron
Chief Business Officer
+972 (54) 222-8901
assafo@biomx.com

Investor Contact
Stern IR, Inc.
Kerry Conlin
+1 (212) 362-1200
kerry.conlin@sternir.com

Source: BiomX

Released February 17, 2020